

## Effects of Adenylate Cyclase, Guanylate Cyclase and $K_{ATP}$ Channel Blockade on the Cerebral Blood Flow Response Induced by Adenosine $A_{2B}$ Receptor Agonist in the Rats

Doo Sang YOUN and In Chul SHIN\*

Department of Pharmacology, College of Medicine, Hanyang University, 17 Haengdang-Dong, Sungdong-Ku, Seoul 133-791, South Korea

(Received March 7, 2005; Accepted March 18, 2005)

**Abstract** – This study was performed to investigate the regulatory mechanism of cerebral blood flow of adenosine  $A_{2B}$  receptor agonist in the rats, and to define whether its mechanism is mediated by adenylate cyclase, guanylate cyclase and potassium channel. In pentobarbital-anesthetized, pancuronium-paralyzed and artificially ventilated male Sprague-Dawley rats, all drugs were applied topically to the cerebral cortex. Blood flow from cerebral cortex was measured using laser-Doppler flowmetry. Topical application of an adenosine  $A_{2B}$  receptor agonist, 5'-*N*-ethylcarboxamidoadenosine (NECA; 4  $\mu\text{mol/l}$ ) increased cerebral blood flow. This effect of NECA (4  $\mu\text{mol/l}$ ) was not blocked by pretreatment with adenylate cyclase inhibitor, MDL-12,330 (20  $\mu\text{mol/l}$ ). But effect of NECA (4  $\mu\text{mol/l}$ ) was blocked by pretreatment with guanylate cyclase inhibitor, LY-83,583 (10  $\mu\text{mol/l}$ ) and pretreatment with ATP-sensitive potassium channel inhibitor, glipizide (5  $\mu\text{mol/l}$ ). These results suggest that adenosine  $A_{2B}$  receptor increases cerebral blood flow. It seems that this action of adenosine  $A_{2B}$  receptor is mediated via the activation of guanylate cyclase and ATP-sensitive potassium channel in the cerebral cortex of the rats.

**Keywords** □ adenosine  $A_{2B}$  receptor, 5'-*N*-ethylcarboxamidoadenosine, cerebral blood flow, adenylate cyclase, guanylate cyclase, ATP-sensitive potassium channel

Adenosine is an endogenous nucleotide that modulates many physiological processes. Its actions are mediated by interaction with specific cell membrane receptors. Adenosine  $A_2$  receptors are regarded as coupling to stimulation of adenylate cyclase activity and the production of cAMP (Fredholm *et al.*, 1994) and to mediate the dilator response of cerebral arterioles to adenosine (Edvinsson and Fredholm, 1983). Adenosine level increases in the brain with moderate hypotension, and its increment is related to the regulation of cerebral blood flow (Win *et al.*, 1981). Adenosine is coupled to adenylate cyclase via 2 types of receptor:  $A_1$  receptor that mediates an inhibition of adenylate cyclase and  $A_2$  receptor that mediates a stimulation of the enzyme (Choca *et al.*, 1987; Gerber and Gähwiler, 1994; Jiang *et al.*, 1992; Van Calker *et al.*, 1979). The  $A_1$  and  $A_2$  receptors have distinct distribution in the central nervous system (Bruns *et al.*, 1987; Stone *et al.*, 1988). The adenosine  $A_2$  receptors are further classified as adenosine  $A_{2A}$  receptor and

$A_{2B}$  receptor subtypes based on the potency of agonist and the receptor affinity (Fredholm *et al.*, 1994). And adenosine may cause vasodilatation by increasing intracellular cAMP, so adenosine  $A_2$  receptor may produce vasodilatation in cerebral cortex. The role for adenosine in the regulation of cerebral blood flow has been proposed by a number of investigators (Dirnagl *et al.*, 1994; Wysham *et al.*, 1986). Adenosine  $A_2$  receptor agonist produces a substantial increase in cerebral blood flow but adenosine  $A_1$  receptor agonist has minimal effects (Coney and Marshall, 1998). Although the precise physiological functions of adenosine  $A_{2B}$  receptors remain undefined, role for the adenosine  $A_{2B}$  receptors have been suggested in the regulation of neuroglia functions (Fiebich *et al.*, 1996), myocardial contractility (Liang and Haltiwanger, 1995) and vascular smooth muscle tone (Martin, 1992).

However, little is known about the regulatory mechanism of cerebral blood flow of adenosine  $A_{2B}$  receptor agonist in the rats. This study was performed to examine the regulatory mechanism of cerebral blood flow of adenosine  $A_{2B}$  receptor agonist in the rats, and to define whether its mechanism is mediated by adenylate cyclase, guanylate cyclase and potas-

\*Corresponding author

Tel: 02-2220-0651, Fax: 02-2292-6686

E-mail: icshin@hanyang.ac.kr

sium channel.


## MATERIALS AND METHODS

The experimental animals, male Sprague-Dawley rats (250-300 gm), were categorized into five groups. The first group of these groups was treated only with 5'-N-ethylcarboxamidoadenosine (NECA; 4  $\mu\text{mol/l}$ ), an adenosine  $A_{2B}$  receptor agonist, topically to the cerebral cortex. The second group was treated with MDL-12,330 (20  $\mu\text{mol/l}$ ), an adenylate cyclase inhibitor, topically to the cerebral cortex 10 min before the injection of 4  $\mu\text{mol/l}$  of NECA. The third group was treated with LY-83,583 (10  $\mu\text{mol/l}$ ), an guanylate cyclase inhibitor, topically to the cerebral cortex 10 min before the injection of 4  $\mu\text{mol/l}$  of NECA. The fourth group was treated with glipizide (5  $\mu\text{mol/l}$ ), ATP-sensitive potassium channel inhibitor, topically to the cerebral cortex 10 min before the injection of 4  $\mu\text{mol/l}$  of NECA. Another group was sham-operated animal group. All drugs were purchased from RBI chemical company (USA) and SIGMA chemical company (USA). All drugs except LY-83,583 and glipizide were dissolved in artificial cerebrospinal fluid (composition : 120.00 mM NaCl, 2.8 mM KCl, 22.00 mM  $\text{NaHCO}_3$ , 1.45 mM  $\text{CaCl}_2$ , 1.00 mM  $\text{Na}_2\text{HPO}_4$ , 0.876 mM  $\text{MgCl}_2$ ) prior to administration and applied topically to the cerebral cortex. LY-83,583 and glipizide were dissolved in 1 % ethanol prior to administration and applied topically to the cerebral cortex. The drug administrations were performed in pentobarbital-anesthetized (50 mg/kg, i.p.), pancuronium-paralyzed (0.1 mg/kg/min, i.v.) and artificially ventilated (Harvard, USA), male Sprague-Dawley rats (250-300 gm). Rectal temperature was maintained at  $37\pm 0.5^\circ\text{C}$  with a heating pad, and the rats were placed in a stereotaxic instrument (Kopf, USA) in the prone position and the parietal bone was removed by gradually thinning the bone bilaterally between the temporal and transverse suture lines using a dental burr: a square-shape (5 $\times$ 5 mm) burr hole was made over the right parietal cortex and bone wax was used to achieve hemostasis. The dura mater was carefully removed from the left parietal cortex and the surface of the cortex was superfused with a artificial cerebrospinal fluid. A barrier was fixed caudal to the craniotomy so that when a drug was applied topically to the cortex. Cerebral blood flow levels were measured with a laser-Doppler flowmetry (Laserflo BPM 403A) equipped with a 1-mm-diameter needle probe through the cranial window, where prewarmed artificial CSF saturated with a gas mixture of 95%  $\text{O}_2$ -5%  $\text{CO}_2$  was constantly suffused over the cortical surface. 'Zero' blood flows were determined

in each preparation after sacrifice at the conclusion of the experiment. Blood pressure and heart rate were continuously monitored via a femoral arterial catheter (PE-50) connected to a pressure transducer (Statham P23, USA) and a polygraph (Grass, USA).  $\text{PO}_2$ ,  $\text{PCO}_2$  and pH of arterial blood were measured with blood gas analyzer before and after stereotaxic experiment. All results are expressed as mean $\pm$ SEM with  $P<0.05$  and  $P<0.01$  considered as the level of significance. The statistical analysis of mean values was performed by analysis of variance (ANOVA). Student's *t*-test for paired data was also used for statistical evaluation of the results.

## RESULTS


A representative experiment showing the effects of topical application of NECA on cerebral blood flow is illustrated in Table 1 and Fig.1. Topical application of NECA caused an increase in cerebral blood flow that reached a maximum in 30 min after application. Pretreatment with alloxazine (4  $\mu\text{mol/l}$ ), an adenosine  $A_{2B}$  receptor antagonist, blocked the NECA-induced cerebral blood flow responses. Topical application of NECA (4  $\mu\text{mol/l}$ ) caused an increase in cerebral blood flow that reached a maximum in 30 min after application. The responses evoked by NECA were  $136\pm 13.7$ ,  $138\pm 12.3$ ,  $149\pm 15.2$ ,  $165\pm 18.3$ ,  $164\pm 17.5$ ,  $165\pm 17.6$ ,  $164\pm 16.6$  and  $163\pm 18.8\%$  compared to the value of baseline cerebral blood flow, respectively in 5, 10, 15, 30, 45, 60, 75 and 90 min after topical application of NECA ( $n=10$ , Table 1 and Fig. 1). Baseline cerebral blood flow for these rats were  $100\pm 11.2\%$ . Topical application of an equivalent volume of artificial cerebrospinal fluid did not affect the basal cerebral blood flow. Cerebral blood flow was not




**Fig. 1.** Effects of topical application of 5'-N-ethylcarboxamidoadenosine (NECA; 4  $\mu\text{mol/l}$ ) on cerebral blood flow responses in rats. Values are mean $\pm$ S.E. in 10 rats

**Table I.** Percent changes in cerebral blood flow of 5'-N-ethylcarboxamidoadenosine (NECA; 4  $\mu\text{mol/l}$ ) only, NECA (4  $\mu\text{mol/l}$ ) after pretreatment with MDL-12,330 (MDL; 20  $\mu\text{mol/l}$ ), NECA (4  $\mu\text{mol/l}$ ) after pretreatment with LY-83,583 (LY; 10  $\mu\text{mol/l}$ ) and NECA (4  $\mu\text{mol/l}$ ) after pretreatment with glipizide (GL; 5  $\mu\text{mol/l}$ ). Pretreatment with MDL-12,330, LY-83,583 or glipizide have no effects on cerebral blood flow. Cerebral blood flow is not affected in sham-operated animal group. Data are the mean $\pm$ S.E. \* $p$ <0.05, compared to 0 time cerebral blood flow.


| Treatment     | Cerebral Blood Flow (%) |                 |                 |                 |                 |                 |                 |                 |                 |
|---------------|-------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|               | Minute after Treatment  |                 |                 |                 |                 |                 |                 |                 |                 |
|               | 0                       | 5               | 10              | 15              | 30              | 45              | 60              | 75              | 90              |
| NECA          | 100 $\pm$ 11.3          | 136 $\pm$ 13.7* | 138 $\pm$ 12.3* | 149 $\pm$ 15.2* | 165 $\pm$ 18.3* | 164 $\pm$ 17.5* | 165 $\pm$ 17.6* | 164 $\pm$ 16.6* | 163 $\pm$ 18.8* |
| MDL+NECA      | 100 $\pm$ 13.2          | 129 $\pm$ 13.6* | 134 $\pm$ 13.1* | 142 $\pm$ 16.2* | 157 $\pm$ 16.5* | 159 $\pm$ 19.5* | 157 $\pm$ 18.8* | 158 $\pm$ 17.7* | 155 $\pm$ 16.6* |
| LY+NECA       | 100 $\pm$ 14.1          | 104 $\pm$ 14.4  | 106 $\pm$ 12.9  | 107 $\pm$ 13.3  | 106 $\pm$ 12.5  | 108 $\pm$ 15.1  | 107 $\pm$ 14.3  | 110 $\pm$ 15.8  | 109 $\pm$ 16.5  |
| GL+NECA       | 100 $\pm$ 12.8          | 104 $\pm$ 14.1  | 106 $\pm$ 11.8  | 108 $\pm$ 13.6  | 108 $\pm$ 11.7  | 109 $\pm$ 14.8  | 109 $\pm$ 12.1  | 110 $\pm$ 14.7  | 109 $\pm$ 15.8  |
| sham-operated | 100 $\pm$ 11.6          | 103 $\pm$ 12.9  | 106 $\pm$ 13.6  | 107 $\pm$ 16.5  | 108 $\pm$ 13.2  | 107 $\pm$ 12.7  | 109 $\pm$ 13.6  | 109 $\pm$ 14.2  | 110 $\pm$ 14.9  |




**Fig. 2.** Effects of topical application of 5'-N-ethylcarboxamidoadenosine (NECA; 4  $\mu\text{mol/l}$ ) after pretreatment with MDL-12,330 (20  $\mu\text{mol/l}$ ) on cerebral blood flow responses in rats. Values are mean $\pm$ S.E. in 10 rats.



**Fig. 4.** Effects of topical application of 5'-N-ethylcarboxamidoadenosine (NECA; 4  $\mu\text{mol/l}$ ) after pretreatment with glipizide (5  $\mu\text{mol/l}$ ) on cerebral blood flow responses in rats. Values are mean $\pm$ S.E. in 10 rats.



**Fig. 3.** Effects of topical application of 5'-N-ethylcarboxamidoadenosine (NECA; 4  $\mu\text{mol/l}$ ) after pretreatment with LY-83,583 (10  $\mu\text{mol/l}$ ) on cerebral blood flow responses in rats. Values are mean $\pm$ S.E. in 10 rats.



**Fig. 5.** Changes in cerebral blood flow (CBF) of 5'-N-ethylcarboxamidoadenosine (NECA; 4  $\mu\text{mol/l}$ ) only and NECA (4  $\mu\text{mol/l}$ ) after pretreatment with MDL-12,330 (MDL; 20  $\mu\text{mol/l}$ ) topically. Values are recorded at the end of 30 minutes after topical application of NECA. Values are the mean $\pm$ S.E. in 10 rats.


affected in sham-operated animal group.

Pretreatment with MDL-12,330 (20  $\mu\text{mol/l}$ ) did not attenuate the NECA-induced cerebral blood flow responses; 129 $\pm$ 13.6,


134 $\pm$ 13.1, 142 $\pm$ 16.2, 157 $\pm$ 16.5, 159 $\pm$ 19.5, 157 $\pm$ 18.8, 158 $\pm$ 17.7 and 155 $\pm$ 16.6% compared to the value of baseline cerebral blood flow, respectively in 5, 10, 15, 30, 45, 60, 75 and 90

min after topical application of NECA ( $n=10$ , Table 1, Fig. 2 and Fig. 5). Baseline cerebral blood flow for these rats were  $100\pm 13.2\%$ . Another different groups were treated with MDL-12,330 (10  $\mu\text{mol/l}$ , 30  $\mu\text{mol/l}$ ) did not affect NECA-induced cerebral blood flow responses. Therefore in this study authors chose the middle concentration.

Pretreatment with LY-3,583 (10  $\mu\text{mol/l}$ ) significantly attenuated the NECA-induced cerebral blood flow responses;  $104\pm 14.4$ ,  $106\pm 12.9$ ,  $107\pm 13.3$ ,  $106\pm 12.5$ ,  $108\pm 15.1$ ,  $107\pm 14.3$ ,  $110\pm 15.8$  and  $109\pm 16.5\%$  compared to the value of baseline cerebral blood flow, respectively in 5, 10, 15, 30, 45, 60, 75 and 90 min after topical application of NECA ( $n=10$ , Table 1, Fig. 3 and Fig. 6). Baseline cerebral blood flow for these rats



**Fig. 6.** Changes in cerebral blood flow (CBF) of 5'-N-ethylcarboxamidoadenosine (NECA; 4  $\mu\text{mol/l}$ ) only and NECA (4  $\mu\text{mol/l}$ ) after pretreatment with LY-83,583 (LY; 10  $\mu\text{mol/l}$ ) topically. Values are recorded at the end of 30 minutes after topical application of NECA. Values are the mean $\pm$ S.E. in 10 rats. \* $P<0.01$ , compared to NECA only group.



**Fig. 7.** Changes in cerebral blood flow (CBF) of 5'-N-ethylcarboxamidoadenosine (NECA; 4  $\mu\text{mol/l}$ ) only and NECA (4  $\mu\text{mol/l}$ ) after pretreatment with glipizide (GL; 5  $\mu\text{mol/l}$ ) topically. Values are recorded at the end of 30 minutes after topical application of NECA. Values are the mean $\pm$ S.E. in 10 rats. \* $P<0.01$ , compared to NECA only group.

were  $100\pm 14.2\%$ . Another different groups were treated with LY-83,583 (5  $\mu\text{mol/l}$ , 15  $\mu\text{mol/l}$ ) affected NECA-induced cerebral blood flow responses concentration-dependently.

Pretreatment with glipizide (5  $\mu\text{mol/l}$ ) significantly attenuated the NECA-induced cerebral blood flow responses;  $104\pm 14.1$ ,  $106\pm 11.8$ ,  $108\pm 13.6$ ,  $108\pm 11.7$ ,  $109\pm 14.8$ ,  $109\pm 12.1$ ,  $110\pm 14.7$  and  $109\pm 15.8\%$  compared to the value of baseline cerebral blood flow, respectively in 5, 10, 15, 30, 45, 60, 75 and 90 min after topical application of NECA ( $n=10$ , Table 1, Fig. 4 and Fig. 7). Baseline cerebral blood flow for these rats were  $100\pm 12.8\%$ . Another different groups were treated with glipizide (1  $\mu\text{mol/l}$ , 10  $\mu\text{mol/l}$ ) affected NECA-induced cerebral blood flow responses concentration-dependently. Therefore in this study authors chose the middle concentration. Topical application of MDL-12,330 (20  $\mu\text{mol/l}$ ), LY-83,583 (10  $\mu\text{mol/l}$ ) and glipizide (5  $\mu\text{mol/l}$ ) had no effects on cerebral blood flow. No significant changes in  $\text{PO}_2$ ,  $\text{PCO}_2$  and pH of arterial blood were seen following stereotaxic experiment (Table II).

## DISCUSSION

Adenosine is an endogenous nucleotide that modulates many physiological processes. Its actions are mediated by interaction with specific cell membrane receptors. Four subtypes of adenosine receptors have been cloned:  $A_1$ ,  $A_{2A}$ ,  $A_{2B}$  and  $A_3$ . It is also recognized that adenosine  $A_{2B}$  receptors are coupled to intracellular pathways different from those of adenosine  $A_{2A}$  receptors, a finding that may provide the basis for their distinct physiological role. Pharmacological identification of  $A_{2B}$  receptors, based on their affinity and characteristic order of potency for receptors. Adenosine  $A_{2B}$  receptors participate in the regulation of vascular tone (Webb *et al.*, 1992). Therefore adenosine-induced vasodilation is mediated via adenosine  $A_{2B}$  receptors. In this present study, topical application of NECA, an adenosine  $A_{2B}$  receptor agonist, in anesthetized and artificially ventilated rats elicited an increase in cerebral blood flow. Adenosine plays an important role in many physiological processes. Its actions are mediated by specific cell surface receptors coupled to G proteins (Fredholm *et al.*, 1994; Olah and Stiles, 1996). Adenosine vasodilates the vasculature of

**Table II.** Summary of blood gas analysis

| Variables              | Before Experiment | After Experiment |
|------------------------|-------------------|------------------|
| $\text{PaCO}_2$ , mmHg | $84.8\pm 2.6\%$   | $88.1\pm 4.2\%$  |
| $\text{PaO}_2$ , mmHg  | $38.9\pm 2.3\%$   | $40.7\pm 1.7\%$  |
| pH                     | $7.22\pm 0.35$    | $7.28\pm 0.42$   |

skeletal muscle and the brain (Mian and Marshall, 1991; Skinner and Marshall, 1996; Thomas and Marshall, 1994). Ngai (Ngai and Winn, 1993) investigated the receptors involved in adenosine-induced dilation in cerebral resistance arterioles and adenosine acts primarily via  $A_2$  receptors to elicit cerebral vasodilation. Some experimental evidences suggest that adenosine receptor plays a critical role in the mediation of cerebral blood flow responses (Van Calker *et al.*, 1979; Hong *et al.*, 1999), and some experimental evidences suggest that adenosine  $A_2$  receptor agonist produces a substantial increase in cerebral blood flow (Coney and Marshall, 1998; Van Wylen *et al.*, 1989). The adenosine  $A_2$  receptor is further classified as adenosine  $A_{2A}$  receptor and  $A_{2B}$  receptor subtypes based on the potency of agonist and the receptor affinity (Fredholm *et al.*, 1994). Cloning techniques have confirmed the existence of distinct  $A_{2A}$  receptor and  $A_{2B}$  receptor subtypes of  $A_2$  receptor (Stehle *et al.*, 1992). Although the precise physiological functions of the  $A_{2B}$  receptors remain undefined, roles for the  $A_{2B}$  receptor has been suggested in the regulation of intestinal chloride secretion (Strohmeier *et al.*, 1995). Hong *et al.* (Hong *et al.*, 1999) demonstrated that when the cortical surface is suffused with cAMP, the release of adenosine is increased in the artificial cerebrospinal fluid and they suggested that the cAMP-adenosine pathway as a metabolic mechanism is implicated in the production of adenosine in the rat pial artery and contributes to the regulation of vasodilation in response to hypotension. But little is known about the regulatory mechanism of cerebral blood flow of adenosine  $A_{2B}$  receptor agonist. And adenosine  $A_{2B}$  receptor agonist produces vasodilation of rat pial artery and cerebral blood flow autoregulation (Shin *et al.*, 2000). In the present study NECA, adenosine  $A_{2B}$  receptor agonist, produces a substantial increase in cerebral blood flow. Martin and Potts (Martin and Potts, 1994) demonstrated a similar result in that renal artery of rat contains adenosine  $A_{2B}$  receptors that are located on the endothelium.

This effect of NECA (4  $\mu\text{mol/l}$ ) was not blocked by pretreatment with adenylate cyclase inhibitor, MDL-12,330 (20  $\mu\text{mol/l}$ ). Hong *et al.* (Hong *et al.*, 1994; Hong *et al.*, 1996) demonstrated that the vasodilation of the pial artery is closely related with accumulation of intracellular cAMP. An involvement of the metabolic AMP-adenosine pathway was demonstrated as a likely mechanism in the production of adenosine that acted as a regulator of vasodilation in response to hypotension (Hong *et al.*, 1999). And adenosine may cause vasodilatation by increasing intracellular cAMP, so adenosine  $A_2$  receptor may produce vasodilatation in cerebral cortex by stimulation of adenylate

cyclase. But the role of adenosine  $A_{2B}$  receptor agonist in the cerebral blood flow response is not related to cAMP.

This effect of NECA (4  $\mu\text{mol/l}$ ) was blocked by pretreatment with guanylate cyclase inhibitor, LY-83,583 (10  $\mu\text{mol/l}$ ). The level of cyclic GMP in vascular smooth muscle is an important regulator of blood flow. Many vasodilators work through increases in cyclic GMP (Hyman *et al.*, 1989; Zhou and Torphy, 1991). Generally NO production leads to increase in the level of cyclic GMP and may help couple cerebral blood flow and metabolism (Dirnagl *et al.*, 1993). It is also believed that NO is involved in the coupling of neurotransmitter receptor stimulation with cellular cyclic GMP responses (Garthwaite, 1988). In this present study adenosine  $A_{2B}$  receptor is mediated by stimulation of guanylate cyclase. Therefore adenosine  $A_{2B}$  receptor may increase cerebral blood flow by increasing intracellular cGMP. So adenosine  $A_{2B}$  receptor may produce vasodilatation in cerebral cortex by stimulation of guanylate cyclase. We demonstrated that NECA-induced vasodilatation in cerebral cortex was significantly inhibited by guanylate cyclase inhibitor, LY-83,583, but not by adenylate cyclase inhibitor, MDL-12,330. Therefore the regulation of cerebral blood flow in adenosine  $A_{2B}$  receptor is mediated by guanylate cyclase. In further study we may determine the level of cGMP level to confirm this evidence.

This effect of NECA (4  $\mu\text{mol/l}$ ) was blocked by pretreatment with ATP-sensitive potassium channel inhibitor, glibenclamide (5  $\mu\text{mol/l}$ ). Some authors report that the action of adenosine is mediated via the activation of potassium channel (Trussel and Jackson, 1985; Nicoll, 1988; Gerber and Gähwiler, 1994). Adenosine receptor and GABA (Gamma-amino butyric acid) receptor act via the activation of potassium channel in substantia nigra (Watt *et al.*, 1995). It is known that ATP-sensitive potassium channel inhibitor is involved in the peripheral response of adenosine  $A_2$  receptor. Therefore the regulation of cerebral blood flow in adenosine  $A_{2B}$  receptor is mediated by potassium channel.

In conclusion, our results show that adenosine  $A_{2B}$  receptor increases cerebral blood flow and this action of adenosine  $A_{2B}$  receptor is mediated by the activation of guanylate cyclase and ATP-sensitive potassium channel in the cerebral cortex of the rats.

## REFERENCES

- Bruns, R. F., Fergus, J. H., Badger, E. W., Bristol, J. A., Santay, L. A., Hartman, J. D., Hays, S. J. and Huang, C. C. (1987).

- Binding of the A<sub>1</sub>-selective adenosine antagonist 8-cyclopentyl-1,3-dipropylxanthine to rat brain membranes. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 335, 59-63.
- Choca, J. I., Proudfoot, H. K. and Green, R. D. (1987). Identification of A<sub>1</sub> and A<sub>2</sub> adenosine receptors in the rat spinal cord. *J. Pharmacol. Exp. Ther.* 242, 905-910.
- Coney, A. M. and Marshall, J. M. (1998). Role of adenosine and its receptors in the vasodilatation induced in the cerebral cortex of the rat by systemic hypoxia. *J. Physiol.* 509, 507-518.
- Dirnagl, U., Lindauer, U. and Villringer, A. (1993). Role of nitric oxide in the coupling of cerebral blood flow to neuronal activation in rats. *Neurosci. Lett.* 149, 43-46.
- Edvinsson, L. and Fredholm, B. B. (1983). Characterization of adenosine receptors in isolated cerebral arteries of cat. *Br. J. Pharmacol.* 80, 631-637.
- Fiebich, B. L., Biber, K., Gyufko, K., Berger, M., Bauer, J. and Van-Calker, D. (1996). Adenosine A<sub>2b</sub> receptors mediate an increase in interleukin(IL)- mRNA and IL-6 protein synthesis in human astroglia cells. *J. Neurochem.* 66, 1426-1431.
- Fredholm, B. B., Abbrachio, M. P., Burnstock, G., Daly, J. W., Harden, T. K., Jacobson, K. A., Leff, P. and Williams, M. (1994). Nomenclature and classification of purinoceptors. *Pharmacol. Rev.* 46, 143-156.
- Garthwaite, J., Charles S. L. and Chess-Williams R. (1988). Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. *Nature* 336, 385-388.
- Gerber, U. and Gähwiler, B. H. (1994). GABA<sub>B</sub> and adenosine receptors mediate enhancement of the K<sup>+</sup> current, I<sub>AHP</sub>, by reducing adenylate cyclase activity in rat CA3 hippocampal neurons. *J. Neurophysiol.* 72, 2360-2367.
- Hong, K. W., Pyo, K. M., Lee, W. S., Yu, S. S and Rhim, B. Y. (1994). Pharmacological evidence that calcitonin-related peptide is implicated in cerebral autoregulation. *Am. J. Heart. Circ. Physiol.* 266, H11-H16.
- Hong, K. W., Shin, H. K., Kim, H. H., Choi, J. M., Rhim, B. Y. and Lee W. S. (1999). Metabolism of exogenous cAMP to adenosine and its role for vasodilation during cerebral autoregulation in rat pial artery. *Am. J. Heart. Circ. Physiol.* 276, H376-H382.
- Hong, K. W., Yoo, S. E., Yu, S. S., Lee, J. Y. and Rhim, B. Y. (1996). Pharmacological coupling and functional role for CGRP receptors in the vasodilation of rat pial arterioles. *Am. J. Heart. Circ. Physiol.* 270, H317-H323.
- Hyman, A. L., Kadowitz, P. J. and Lipton, H. L. (1989). Methylene blue selectively inhibits pulmonary vasodilator responses in cats. *J. Appl. Physiol.* 66, 1513-1517.
- Jiang, H., Colbran, J. L., Francis, S. H. and Corbin, J. D. (1992). Direct evidence for cross-activation of cGMP-dependent protein kinase by cAMP in pig coronary arteries. *J. Biol. Chem.* 267, 1015-1019.
- Liang, B. T. and Haltiwanger, B. (1995). Adenosine A<sub>2a</sub> and A<sub>2b</sub> receptors in cultured fetal chick heart cells. High-and low-affinity coupling to stimulation of myocyte contractility and cAMP accumulation. *Circ. Res.* 76, 242-251.
- Martin, P. L. (1992). Relative agonist potencies of C2-substituted analogs of adenosine: evidence for adenosine A<sub>2B</sub> receptors in the guinea pig aorta. *Eur. J. Pharmacol.* 216, 235-242.
- Martin, P. L. and Potts, A. A. (1994). The endothelium of the rat renal artery plays an obligatory role in A<sub>2</sub> adenosine receptor-mediated relaxation induced by 5'-N-ethylcarboxamidoadenosine and N<sup>6</sup>-cyclopentyladenosine. *J. Pharmacol. Exp. Ther.* 270, 893-899.
- Mian, R. and Marshall, J. M. (1991). The role of adenosine in dilator responses induced in arterioles and venules of rat skeletal muscle by systemic hypoxia. *J. Physiol.* 443, 499-511.
- Ngai, A. C. and Winn, H. R. (1993). Effects of adenosine and its analogues on isolated arterioles: extraluminal and intraluminal application. *Circ. Res.* 73, 448-457.
- Nicoll, R. A. (1988). The coupling of neurotransmitter receptor to ion channels in the brain. *Science* 241, 545-551.
- Olah, M. E. and Stiles, G. L. (1996). Adenosine receptor subtypes: characterization and therapeutic regulation. *Annu. Rev. Pharmacol. Toxicol.* 35, 581-606.
- Shin, H., K., Shin, Y., W. and Hong, K., W. (2000). Role of adenosine A<sub>2B</sub> receptors in vasodilation of rat pial artery and cerebral blood flow autoregulation. *Am. J. Physiol.-Heart and Circulatory Physiology* 278, H339-H344.
- Skinner, M. R. and Marshall, J. M. (1996). Studies on the roles of ATP, adenosine and nitric oxide in mediating muscle vasodilation induced in the rat by acute systemic hypoxia. *J. Physiol.* 495, 553-560.
- Stehle, J. H., Rivkees, S. A., Lee, J. J., Weaver, D. R., Deeds, J. D. and Reppert, S. M. (1992). Molecular cloning and expression of the cDNA for a novel A<sub>2</sub>-adenosine receptor subtype. *Mol. Endocrinol.* 6, 384-393.
- Stone, G. A., Jarvis, M. F., Sills, M. S., Weeks, B., Snowhill, E. W. and Williams, M. (1988). Species differences in high affinity adenosine A<sub>2</sub> binding sites in striatal membranes from mammalian brain. *Drug Develop. Res.* 15, 31-46.
- Strohmeier, G. R., Reppert, S. M., Lencer, W. I. and Madara, J. L. (1995). The A<sub>2b</sub> adenosine receptor mediates camp responses to adenosine receptor agonists in human intestinal epithelia. *J. Biol. Chem.* 270, 2387-2941.
- Thomas, T. and Marshall, J. M. (1994). Interdependence of respiratory and cardiovascular changes induced by systemic hypoxia in the rat: the role of adenosine. *J. Physiol.* 480, 627-636.
- Trussel, L. O. and Jackson, M. B. (1985). Adenosine-activated potassium conductance in cultured striatal neurons. *Proc. Natl. Acad. Sci. USA.* 82, 4857-4861.
- Van Calker, D., Muller, M. and Hamprecht, B. (1979). Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. *J. Neurochem.* 33, 999-1005.
- Van Wylen, D. G. L., Park, T. S., Rubio, R. and Berne, R. M. (1989). The effect of local infusion of adenosine and adenosine analogues on local cerebral blood flow. *J. Cereb. Blood. Flow. Metab.* 9, 556-562.
- Watts, A.E., Hicks, G. A. and Henderson, G.(1995). Putative pre- and postsynaptic ATP-sensitive potassium channels in the rat substantia nigra in vitro. *J. Neurosci.* 15(4), 3065-3074.
- Webb, R. L., Sills, M. A., Chovan, J. P., Balwierczak, J. L. and Francis, J. E. (1992). CGS21680: a potent selective adenosine A<sub>2</sub> receptor agonist. *Cardiovasc. Drug Rev.* 10, 26-53.1
- Winn, H. R., Rubio, R. and Berne, R. M. (1981). The role of adenosine in the regulation of cerebral blood flow. *J. Cereb. Blood. Flow. Metab.* 1, 239-244.
- Wysham, D. G., Brotherton, A. F. and Heistad, D. D. (1986). Effects of forskolin on cerebral blood flow : Implications for a role of adenylate cyclase. *Stroke* 17, 1299-1303.
- Yoneyama, F., Yamada, H., Satoh, K. and Taira, N. (1992). Vasodepressor mechanism of 2-(1-octynyl)-adenosine (YT-146), a selective adenosine A<sub>2</sub> receptor agonist, involve the opening of glibenclamide-sensitive K<sup>+</sup> channels. *Eur. J. Pharmacol.* 213, 199-204.
- Zhou, H. L. and Torphy, T. J. (1991). Relationship between cyclic guanosine monophosphate accumulation and relaxation of canine trachealis induced by nitrovasodilators. *J. Pharmacol. Exp. Ther.* 258, 972-978.